Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

HAVG

Other · developed by Humacyte

Phase 1 Most advanced trial (none active)

HUMA Developer

1 Registered trials

What is HAVG?

HAVG is implanted into patients' arm for end-stage renal disease and chronic kidney failure.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Renal & urology
Developer: Humacyte, Inc. (HUMA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01840956	Phase 1	End-stage Renal Disease	Completed	HUMA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

End-stage Renal DiseaseKidney Failure, Chronic

More from Humacyte

Acellular Tissue Engineered Vessel FDA approved Humacyte Coronary Tissue Engineered Vessel Phase 2

Sources

ClinicalTrials.gov NCT01840956

Updated Oct 3, 2026. Something wrong or missing? Report it on the HUMA page.

Follow HUMA, the company behind HAVG

See HUMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HUMA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z